Equities research analysts expect that Medidata Solutions (NASDAQ:MDSO) will post sales of $156.27 million for the current quarter, Zacks reports. Seven analysts have issued estimates for Medidata Solutions’ earnings. The lowest sales estimate is $155.20 million and the highest is $158.40 million. Medidata Solutions posted sales of $137.41 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 13.7%. The business is expected to announce its next earnings report on Tuesday, July 17th.
According to Zacks, analysts expect that Medidata Solutions will report full year sales of $637.24 million for the current financial year, with estimates ranging from $634.10 million to $641.43 million. For the next financial year, analysts forecast that the company will post sales of $748.93 million per share, with estimates ranging from $740.80 million to $770.54 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Medidata Solutions.
Get Medidata Solutions alerts:
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, April 19th. The company reported $0.40 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.05. The firm had revenue of $149.20 million during the quarter, compared to analyst estimates of $146.73 million. Medidata Solutions had a net margin of 7.96% and a return on equity of 11.36%. Medidata Solutions’s revenue was up 16.9% on a year-over-year basis. During the same period last year, the firm posted $0.31 EPS.
Several equities analysts recently commented on the stock. BidaskClub raised shares of Medidata Solutions from a “hold” rating to a “buy” rating in a research report on Friday. Zacks Investment Research lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Thursday, April 26th. ValuEngine raised shares of Medidata Solutions from a “sell” rating to a “hold” rating in a research report on Thursday, April 12th. Needham & Company LLC increased their price objective on shares of Medidata Solutions to $80.00 and gave the company a “buy” rating in a research report on Friday, April 20th. Finally, TheStreet raised shares of Medidata Solutions from a “c+” rating to a “b-” rating in a research report on Monday, March 12th. Four equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $82.71.
Shares of Medidata Solutions stock traded up $1.77 during midday trading on Friday, hitting $76.88. The company had a trading volume of 388,212 shares, compared to its average volume of 615,778. The firm has a market capitalization of $4.45 billion, a P/E ratio of 90.61, a PEG ratio of 3.77 and a beta of 1.49. The company has a quick ratio of 1.49, a current ratio of 1.63 and a debt-to-equity ratio of 0.18. Medidata Solutions has a 12-month low of $59.60 and a 12-month high of $85.92.
In other news, CFO Rouven Bergmann sold 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 19th. The shares were sold at an average price of $71.50, for a total transaction of $286,000.00. Following the sale, the chief financial officer now owns 93,744 shares of the company’s stock, valued at approximately $6,702,696. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael I. Otner sold 10,395 shares of the firm’s stock in a transaction that occurred on Wednesday, April 25th. The stock was sold at an average price of $70.05, for a total transaction of $728,169.75. Following the sale, the executive vice president now directly owns 74,165 shares in the company, valued at approximately $5,195,258.25. The disclosure for this sale can be found here. Insiders have sold a total of 45,231 shares of company stock valued at $3,166,939 over the last three months. 4.70% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Medidata Solutions by 48.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,242 shares of the company’s stock worth $205,000 after purchasing an additional 1,056 shares during the period. Meadow Creek Investment Management LLC grew its stake in shares of Medidata Solutions by 31.4% during the 4th quarter. Meadow Creek Investment Management LLC now owns 3,680 shares of the company’s stock worth $233,000 after purchasing an additional 880 shares during the period. Polen Capital Management LLC grew its stake in shares of Medidata Solutions by 77.0% during the 4th quarter. Polen Capital Management LLC now owns 4,640 shares of the company’s stock worth $294,000 after purchasing an additional 2,018 shares during the period. Joel Isaacson & Co. LLC acquired a new stake in shares of Medidata Solutions during the 1st quarter worth approximately $314,000. Finally, Brown Advisory Securities LLC acquired a new stake in shares of Medidata Solutions during the 4th quarter worth approximately $356,000.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Get a free copy of the Zacks research report on Medidata Solutions (MDSO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com